Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2004 Dec;6(12):682-9.
doi: 10.1111/j.1524-6175.2004.03707.x.

Different effects of losartan and moxonidine on endothelial function during sympathetic activation in essential hypertension

Michael N Doumas  1 , Stella N Douma, Kostas M Petidis, Kostas V Vogiatzis, Ilias C Bassagiannis, Chris X Zamboulis
Affiliations
Clinical Trial

Different effects of losartan and moxonidine on endothelial function during sympathetic activation in essential hypertension

Michael N Doumas et al. J Clin Hypertens (Greenwich). 2004 Dec.

Abstract

The aim of this study was to investigate: 1) the effects of treadmill exercise on plasma catecholamines and endothelin-1 (ET-1, a potent vasoconstrictor) levels in hypertensive patients; and 2) the impact of 1-month therapy with losartan as compared with moxonidine on catecholamine and ET-1 changes during exercise. Twenty-eight patients with essential hypertension were randomized in two groups: group A received losartan and group B received moxonidine for 1 month. Plasma catecholamines exhibited an almost 10-fold increase during exercise (p<0.00001) before treatment. Moxonidine significantly decreased catecholamine levels (p<0.05), while losartan reduction was nonsignificant (p<0.36). Plasma ET-1 increased significantly during exercise before treatment (p<0.00005). Moxonidine therapy did not affect ET-1 levels (p<0.88), while losartan resulted in a significant decrease of ET-1 levels both at baseline and during exercise (p<0.007). These findings suggest a mechanism for the reduced cardiovascular mortality noted with an angiotensin receptor blocker as compared with a sympatholytic agent.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Systolic blood pressure changes during exercise before (pre) and after treatment with losartan (los) and moxonidine (mox)
Figure 2
Figure 2
Plasma noradrenaline (pg/mL) changes during exercise before (pre) and after treatment with losartan (los) and moxonidine (mox)
Figure 3
Figure 3
Plasma adrenaline (pg/mL) changes during exercise before (pre) and after treatment with losartan (los) and moxonidine (mox)
Figure 4
Figure 4
Plasma endothelin‐1 (pg/mL) changes during exercise before (pre) and after treatment with losartan (los) and moxonidine (mox)
See this image and copyright information in PMC

References

    1. Dahlof B, Devereux R, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): randomized trial against atenolol. Lancet. 2002;359:995–1003. - PubMed
    1. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252. - PubMed
    1. 2003. European Society of Hypertension‐European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011–1053. - PubMed
    1. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A. 1989;86:2863–2867. - PMC - PubMed
    1. Saida K, Mitsui Y, Ishida N. A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family: molecular cloning, expression and biological activity. J Biol Chem. 1989;264:14613–14616. - PubMed

MeSH terms